[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100506567":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":36,"locations":41,"responsibleParty":58,"collaborators":26,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":26,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":26,"enrollmentInfo":70,"targetDuration":26,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":26,"overallStatus":44,"whyStopped":26,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"RenJi Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"capecitabine and cyclophosphamide (XC)","EXPERIMENTAL","capecitabine and cyclophosphamide as maintenance therapy every 3 weeks",[13],"Drug: XC",{"label":15,"type":16,"description":17,"interventionNames":18},"physician's choice","ACTIVE_COMPARATOR","Any physician's choice as maintenance therapy (except for XC regimen).",[19],"Drug: TPC",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","XC","Capecitabine (bid po, d1-14) and cyclophosphamide (qd po, d1-d14) every 21 days",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"TPC","Any physician's choice as maintenance therapy (except for XC regimen)",[15],[32],{"name":33,"affiliation":34,"role":35},"Wenjin Yin, M.D.","Renji Hospital,School of Medicine, Shanghai Jiaotong University","PRINCIPAL_INVESTIGATOR",[37],{"name":33,"role":38,"phone":39,"phoneExt":26,"email":40},"CONTACT","86(21)68385569","yinwenjin@renji.com",[42],{"facility":43,"status":44,"city":45,"state":26,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Renji Hospital, School of Medicine, Shanghai Jiaotong University","RECRUITING","Shanghai","200127","China","CN",{"type":50,"coordinates":51},"Point",[52,53],121.45806,31.22222,{"lat":53,"lon":52},[56],{"name":57,"role":38,"phone":39,"phoneExt":26,"email":40},"Wenjin Yin",{"type":59,"investigatorFullName":57,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"SPONSOR_INVESTIGATOR","Deputy Chief of Breast Surgery Department","100506567","capecitabine-and-cyclophosphamide-xc-as-maintenance-therapy-for-advanced-breast-cancer-100506567",false,"NCT05876065","Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer","Efficacy and Safety of Capecitabine and Cyclophosphamide (XC) Versus Physician's Choice as Maintenance Therapy for Advanced Breast Cancer: a Randomized, Controlled, Open-label Clinical Trial","Inclusion Criteria:\n\n* Female, age≥18 years old\n* ECOG≤2\n* Pathologically confirmed primary breast cancer, with pathologically or radiologically confirmed recurrent or metastatic lesions\n* HR+\u002FHER2+ or HR-\u002FHER2+ or HR-\u002FHER2-\n* At least one measurable lesion or bone-only disease (osteolytic or mixed) according to RECIST v1.1\n* Disease control (complete response + partial response + stable disease) after salvage treatment\n* Expected survival ≥6 months\n* Adequate organ function\n\nExclusion Criteria:\n\n* during pregnancy and lactation\n* Patients with central nervous system metastasis","FEMALE","18 Years",{"count":71,"type":72},86,"ESTIMATED","INTERVENTIONAL",[75],"NA","To compare the efficacy and safety of capecitabine and cyclophosphamide (XC) versus physician's choice as maintenance therapy for patients with advanced breast cancer who achieved disease control after salvage treatment.",[78],"Advanced Breast Cancer","2026-08-17",{"date":81,"type":82},"2026-08-19","ACTUAL",{"date":84,"type":82},"2023-06-01",{"date":86,"type":72},"2028-02",{"name":57,"class":6},1]